老外写的中国OTC市场分析报告

Datamonitor USA 245 Fifth Avenue4th FloorNew York, NY 10016 USAt: +1 212 686 7400 f: +1 212 686 2626 Datamonitor EuropeCharles House108-110 Finchley RoadLondon NW3 5JJUnited Kingdomt: +44 20 7675 7000f: +44 20 7675 7500Datamonitor GermanyKastor & PolluxPlatz der Einheit 160327 FrankfurtDeutschlandt: +49 69 9754 4517f: +49 69 9754 4900Datamonitor Asia PacificLevel 46, 2 Park StreetSydney, NSW 2000Australiat: +61 2 8705 6900f: +61 2 8705 6901OTC Pharmaceuticals inChinaIndustry ProfileReference Code: 0099-0364Publication date: December 2008ABOUT DATAMONITORAll Rights Reserved.No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Datamonitor plc.The facts of this report are believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that Datamonitor delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such Datamonitor can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect.ABOUT DATAMONITORDatamonitor is a leading business information company specializing in industry analysis.Through its proprietary databases and wealth of expertise, Datamonitor provides clients with unbiased expert analysis and in depth forecasts for six industry sectors: Healthcare, Technology, Automotive, Energy, Consumer Markets, and Financial Services.The company also advises clients on the impact that new technology and eCommerce will have on their businesses. Datamonitor maintains its headquarters in London, and regional offices in New York, Frankfurt, and Hong Kong. The company serves the world’s largest 5000 companies.Datamonitor's premium reports are based on primary research with industry panels and consumers. We gather information on market segmentation, market growth and pricing, competitors and products. Our experts then interpret this data to produce detailed forecasts and actionable recommendations, helping you create new business opportunities and ideas.Our series of company, industry and country profiles complements our premium products, providing top-level information on 10,000 companies, 2,500 industries and 50 countries. While they do not contain the highly detailed breakdowns found in premium reports, profiles give you the most important qualitative and quantitative summary information you need - including predictions and forecasts.EXECUTIVE SUMMARYEXECUTIVE SUMMARYMarket ValueThe Chinese OTC pharmaceuticals market grew by 7.1% in 2008 to reach a value of $16.1 billion.Market Value ForecastIn 2013, the market is forecast to have a value of $21.9 billion, an increase of 36.0% since 2008.Market Segmentation ITraditional medicines sales account for 51% of the Chinese OTC pharmaceuticals market's value.Market Segmentation IIChina generates 40.6% of the Asia-Pacific OTC pharmaceuticals market's value.Market ShareNin-Jiom is the largest company in the Chinese OTC pharmaceuticals market, generating 6.6% of its value.DistributionPharmacies and drugstores distribute 56.2% of the Chinese OTC pharmaceuticals market's overall value.TABLE OF CONTENTSEXECUTIVE SUMMARY 3 CHAPTER 1Market Overview 7 1.1Market Definition 7 1.2Research Highlights 7 1.3Market Analysis 8 CHAPTER 2Market Value 9 CHAPTER 3Market Segmentation I 10 CHAPTER 4Market Segmentation II 11 CHAPTER 5Market Share 12 CHAPTER 6Competitive Landscape 13 CHAPTER 7Leading Companies 16 7.1Nin Jiom Medicine Manufactory Limited 16 7.2Huangshan Tianmu Pharmaceutical Co., Ltd. 17 7.3Johnson & Johnson 18 CHAPTER 8Distribution 21 CHAPTER 9Market Forecasts 22 9.1Market Value Forecast 22 CHAPTER 10Macroeconomic Indicators 23CHAPTER 11Appendix 25 11.1Methodology 25 11.2Industry Associations 26 11.3Related Datamonitor Research 26LIST OF TABLESTable 1:China OTC Pharmaceuticals Market Value: $ billion, 2004- 2008(e) (9)Table 2:China OTC Pharmaceuticals Market Segmentation I: % Share, by Value, 2008(e) (10)Table 3:China OTC Pharmaceuticals Market Segmentation II: % Share, by Value, 2008(e) (11)Table 4:China OTC Pharmaceuticals Market Share: % Share, by Value, 2007 (12)Table 5:Key Facts: Nin Jiom Medicine Manufactory Limited (16)Table 6:Key Facts: Huangshan Tianmu Pharmaceutical Co., Ltd (17)Table 7:Key Facts: Johnson & Johnson (18)Table 8:Key Financials: Johnson & Johnson (20)Table 9:China OTC Pharmaceuticals Distribution: % Share, by Value, 2008(e) (21)Table 10:China OTC Pharmaceuticals Market Value Forecast: $ billion, 2008-2013 (22)Table 11:China Size of Population (million) , 2004-2008(e) (23)Table 12:China GDP (Constant 2000 Prices, $ billion), 2004-2008(e) (23)Table 13:China Inflation, 2004-2008(e) (23)Table 14:China Exchange Rate, 2004-2008(e) (24)CHAPTER 1 MARKET OVERVIEW1.1 Market DefinitionThe OTC pharmaceuticals market values the total sales of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers),vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin, other analgesics), and other OTC healthcare products including;medicated skin products (anti-bacterials, acne treatments, anti-fungals, other medicated skin products, disinfectants), topical OTC medicines (anesthetic products,anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, other tape or bandage, liquid bandages), first aid kits and other OTC healthcare products (anti-smoking aids,rectal medications, eye/ear drops, sleeping aids, motion sickness).The market values are at retail selling price (RSP) and include any applicable taxes.Any currency conversions used in the creation of this report have been calculated using constant 2007 annual average exchange rates.Asia-Pacific comprises Australia, China, Japan, India, Singapore, South Korea and Taiwan.1.2 Research HighlightsThe Chinese OTC pharmaceuticals market generated total revenues of $16.1 billionin 2008, representing a compound annual growth rate (CAGR) of 7% for the periodspanning 2004-2008.Sales of traditional medicines proved the most lucrative for the Chinese OTC pharmaceuticals market in 2008, generating total revenues of $8.2 billion, equivalentto 51% of the market's overall value.The performance of the market is forecast to decelerate, with an anticipated CAGR of6.3% for the five-year period 2008-2013, which is expected to drive the market to avalue of $21.9 billion by the end of 2013.1.3 Market AnalysisThe Chinese OTC pharmaceuticals market generated total revenues of $16.1 billion in 2008, representing a compound annual growth rate (CAGR) of 7% for the period spanning 2004-2008. In comparison, the Japanese and Indian markets grew with CAGRs of 1.6% and 6.4%, respectively, over the same period, to reach respective values of $14.5 billion and $1.8 billion in 2008.Sales of traditional medicines proved the most lucrative for the Chinese OTC pharmaceuticals market in 2008, generating total revenues of $8.2 billion, equivalent to 51% of the market's overall value. In comparison, sales of cough and cold preparations generated revenues of $1.6 billion in 2008, equating to 10.1% of the market's aggregate revenues.The performance of the market is forecast to decelerate, with an anticipated CAGR of6.3% for the five-year period 2008-2013, which is expected to drive the market to avalue of $21.9 billion by the end of 2013. Comparatively, the Japanese and Indian markets will grow with CAGRs of 1.3% and 5.2%, respectively, over the same period, to reach respective values of $15.5 billion and $2.3 billion in 2013.MARKET VALUECHAPTER 2 MARKET VALUEThe Chinese OTC pharmaceuticals market grew by 7.1% in 2008 to reach a value of $16.1 billion.The compound annual growth rate of the market in the period 2004-2008 was 7%.Year $ billion RMB yuan % Growthbillion2004 12.3 93.82005 13.2 100.2 6.90%2006 14.1 107.3 7.10%2007 15.1 114.8 7.00%2008(e) 16.1 122.9 7.10%CAGR, 2004-2008: 7.0%Source: Datamonitor D A T A M O N I T O RMARKET SEGMENTATION ICHAPTER 3 MARKET SEGMENTATION ITraditional medicines sales account for 51% of the Chinese OTC pharmaceuticalsmarket's value.In comparison, cough and cold preparations account for 10.1%.ShareCategory % Traditional medicines 51.00%Cough and cold preparations 10.10%Indigestion preparations 7.50%Vitamins and minerals 6.20%Analgesics 4.70%Other 20.50%Total 100.0%Source: DatamonitorD A T A M O N I T O RMARKET SEGMENTATION IICHAPTER 4 MARKET SEGMENTATION IIChina generates 40.6% of the Asia-Pacific OTC pharmaceuticals market's value.In comparison, the Japanese market accounts for 36.6% of the Asia-Pacific market's value.Geography % ShareChina 40.60%Japan 36.60%South Korea 8.40%India 4.50%Rest of Asia-Pacific 10.00%Total 100.0%Source: DatamonitorD A T A M O N I T O RMARKET SHARECHAPTER 5 MARKET SHARENin-Jiom is the largest company in the Chinese OTC pharmaceuticals market,generating 6.6% of its value.Huangshan Tianmu Pharmaceuticals Company accounts for a further 6.5% of themarket's value.2007ShareCompany %Nin Jiom 6.60%6.50%Huangshan Tianmu PharmaceuticalsCompany LimitedJohnson & Johnson 3.30%Other 83.60%Total 100.0%Source: DatamonitorD A T A M O N I T O RCHAPTER 6 COMPETITIVE LANDSCAPEThe OTC pharmaceuticals market has manufacturers as players, and distributors such as pharmacies and supermarkets as buyers. Suppliers include manufacturers of active pharmaceutical ingredients, and supplier power is strong. Market entry is made more difficult by the product development costs where a new drug is concerned, and by the need to obtain regulatory approval for products. Prescription drugs are the main substitutes, but the threat they pose is weak: they are frequently used in situations where no adequate OTC remedy exists. Rivalry is strong, with large research-based pharma players and major companies involved in household and personal care fight with smaller generics manufacturers for market share.This market will be analyzed taking the distributors of drugs, including pharmacies, general stores and supermarkets, as buyers. In China, pharmacies and drugstores form the most important distribution channel for OTC drugs. These distributors have less buyer power than the large supermarkets, due to their smaller size. Moreover, large pharmaceutical companies with recognised brands wield considerable power over smaller pharmacies and drug stores, reducing buyer power. Retailers often wield significant power in supply chains, however, consumer preference for a wide availability of self-medication options forces buyers in this market to stock OTC pharmaceuticals. However, OTC drugs are much more important to the business of pharmacies than supermarkets and as a result buyers' switching costs can differ slightly in this market. Buyers in this market tend to integrate backward but this is not common. However, whenever it takes place such integration can increase pressure on market players, enhencing buyer power at the same time. Overall buyer power is moderate.Suppliers in the market are mainly manufacturers of Active Pharmaceutical Ingredients (API). Market players require a wide range of specialized ingredients, which maintains supplier power. However many large pharmaceutical companies have operations in chemical manufacturing. The example here would be Teva Pharmaceuticals which has established back integration and manufactures a number of API products. Merck & Co also has its own chemicals division. Smaller pharmaceutical companies do not operate facilities sophisticated enough to manufacture chemical ingredients themselves and therefore are often heavily reliant upon API manufacturers. Although some chemical manufacturers only supply to pharmaceutical companies, many also supply to numerous industries and develop chemicals for food ingredients, animal feed and suspensions and ceramics, reducing their dependence on revenues gained from pharmaceutical supply. APIs are most often supplied to pharmaceutical companies under contractual arrangements, increasing switching costs and enhancing the power of suppliers. Overall supplier power is strong.The over the counter drug market involves a high level of specialization and expertise with high upfront investment costs, making the market difficult to enter. The main costs are incurred from extensive clinical trials. Large companies have an advantage as scale economies can help to achieve success in the R&D process. Despite this smaller firms are prevalent in the market and can still achieve efficiency through collaborations with larger firms which allows them to benefit from increased funds, creating more innovation and research opportunities. The most realistic entry method would be as a small generic drug firm; a much less costly business model than branded drug manufacture. The regulatory body for drug approval in China is the State Food and Drug Administration. There are opportunities for new companies in over-the-counter drugs with the strong growth of the market. This is being fostered by an ageing population and by a global trend toward self medication. In the pharmaceutical industry product recalls can damage brand image and issues over the safety of drugs can impact end users decision to purchase OTC drugs, lowering switching costs. Even in this market where some products are highly important to the end user, customer preferences can have a strong pull-through on manufacturers. However it is unusual for an OTC drug to be withdrawn from the market due to safety issues although there have been a few instances. Drugs often become over the counter by switching from a prescription drug which can increase consumer confidence in the product. Overall the threat of new entrants is moderate.Prescription drugs offer an obvious substitute to OTC pharmaceuticals, but these are normally suited to treating more serious ailments, and thus largely fail to encroach into the OTC market. Moreover most pharmaceutical companies produce both OTC and prescription drugs, which diminishes any threat from this particular substitute. Many consumers now use alternative medicines, like homeopathy but often in conjunction with conventional medicine, thereby making them less threatening, and more complementary. Sustained use of alternative medicines instead of scientific preparations is often linked with adherence to an alternative lifestyle, philosophy or political belief system, like environmentalism. Thus, while there is niche demand for such products, the majority of the populace is unlikely to view alternative medicines as a viable alternative to OTC pharmaceuticals. Traditional remedies are also an important and established substitute in the Chinese market. Overall the threat from substitutes is assessed as weak.The pharmaceutical market is witnessing increasing consolidation leading to bigger companies and more competition. However, these firms have typically high fixed costs, as drug research and development requires continued investment. Exit barriers are fairly high as most companies that manufacture OTC drugs are focused on the pharmaceutical market and are similar to one another. However some personal care companies operate in the over the counter drugs market or even in prescription pharmaceuticals meaning that exit barriers are lowered for these companies.For example Reckitt Benckiser owns the Nurofen and Strepsils brand after acquiring Boots Healthcare International but is also primarily involved in the production and distribution of household cleaning and personal care products. In this market, manufacturers can differentiate by demonstrating a drug has greater clinical benefit than another and also through a strong brand image - Ibuprofen is a popular painkiller but Nurofen is the best known brand of this drug and achieves strong sales. Sales growth has been sustained by innovation and extensions to the product, for example Nurofen fast relief has recently been launched. The growth of this market mitigates rivalry somewhat. Overall, rivalry with respect to the over-the-counter drugs market is moderate.CHAPTER 7 LEADING COMPANIES7.1 Nin Jiom Medicine Manufactory LimitedAddress: 16/F., Block A, Texaco Road Industrial Centre, 256-264Texaco Road, Tsuen Wan, N.T. Hong KongTelephone: 852 2408 8521Fax: 852 2407 6269Website: Source: Company Website D A T A M O N I T O RNin Jiom Medicine Manufactory Limited is one of the leading Chinese medicine manufacturers in Hong Kong. Nin Jiom becomes famous for its main products “Pei Pa Koa" Nin Jiom Herbal Cough Syrup which is popular and available in over 20 countries around the world. Nin Jiom Medicine Manufactory was founded in 1946 and the manufacturing company was incorporated in 1962 in Hong Kong.To cope with the increasing demand for the cough syrup, in 1984 the factory was relocated to the New Territories - with a 90,000 sq. ft. plant with fully-automated production lines and the modernized equipment. The Hong Kong headquarters remains responsible for coordination of the marketing in Hong Kong, Macao, China, Asia, Europe, and the U.S.In 1996 Nin Jiom opened the new Taiwan factory, a 40,000 sq. ft. plant to replace the older facility. The company now has three production facilities: the Hong Kong headquarter responsibles for both production and worldwide marketing, the Taiwan facilities mainly responsibles for developing ingredient concentrates and serving the local Taiwan market, and the Singapore plant as production center specializing in the testing of various prescriptions as well as conducting research for the most efficient way to produce traditional Chinese medicines.At the Singapore plant a series of Chinese herb teas have been successfully developed. They include products labeled Cold Remedy, Livereen, Rehmannia Plus, Bestrong and Femalle.Key Metrics:Since Nin Jiom Medicine is privately held company, there is no financial information available for public.7.2 Huangshan Tianmu Pharmaceutical Co., Ltd.Address: No. 45. Huangshan Middle Road, Huangshan, Anhui, China, Huangshan, Anhui, 245000 China,Telephone: 86 559 2513518Fax: 86 559 2513518Website: Source: Company Website D A T A M O N I T O RHuangshan Tianmu Pharmaceutical Co., Ltd. is composed of Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd. and Huangshan Pharmaceutical General Factory.The company manufactures 12 types of Western Medicines, Chinese Medicines, and Raw Materials. Its most known products are: Menthol Crystals, Peppermint Oil, Gentamycin Injection, Vitamin C Tablets, Norfloxacin Capsules, Lui Wei Di Huang Oral Liquid, Lui Wei Di Huang Condensed Pills, Xiang Dan Injection, Yu Xin Cao Injection, He Che Da Zao Capsules, Tamoxifen Citrate Tablets, etc.Huangshan exports its products to Nigeria, Pakistan, Indonesia, Macau, Hong Kong and other foreign market.The company is located at the foot of Huangshan Mountain and covers an area of 19,300 m2, occupies a quite complete set of production and living facilities, and contains six workshops that satisfying the international GMP standard. There are more than 400 employees.Key MetricsNo financial data available.7.3 Johnson& JohnsonAddress: One Johnson & Johnson Plaza, New BrunswickNew Jersey 08933 USATelephone: 1 732 524 2455Fax: 1 732 214 0332Website: Financial Year-End: DecemberTicker: JNJStock Exchange: New YorkSource: Company Website D A T A M O N I T O RJohnson & Johnson (J&J) is a global manufacturer of health care products as well asa provider of related services.The company operates predominantly through three divisions: consumer, pharmaceuticals and medical devices and diagnostics.J&J's consumer division develops and markets products for baby and kids care, skincare, oral care, wound care, women's health care, nutritional and over-the-counter pharmaceutical products. These products are distributed either through wholesalersor directly to independent and chain retail outlets. Major brands include: Aveeno (skincare products); Band-Aid (adhesive bandages); Carefree (panty liners); Clean & Clear (skin care products for teens); Johnson's baby and adult lines of products;Motrin IB (ibuprofen products); Neutrogena (skin and hair care products); RoC (skincare products); Pepcid AC (acid controller), Merck Consumer Pharmaceuticals.;Rembrandt (oral care products); Splenda (sweetener); Stayfree (sanitary protection products); and Tylenol (acetaminophen products).In December 2006, J&J completed the acquisition of the consumer healthcare business of Pfizer comprising self-medications for oral care, upper-respiratory health,tobacco dependence, gastrointestinal health, skin care, eye care and hair growth products. Familiar brands of the consumer healthcare business of Pfizer include Listerine (oral care products), Nicorette (smoking cessation treatments), and Sudafed(cold, flu and allergy products).The company's pharmaceutical division produces and markets products in the following therapeutic areas: anti-fungal, anti-infective, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, psychotropic (central nervous system), urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals.Major brands include: Risperdal (risperidone) and Risperdal Consta (risperidone long-acting injection), for treatment of the symptoms of schizophrenia; Procrit (epoetin alfa, sold outside the US as Eprex, a red blood cell production stimulant; Remicade (infliximab), to treat the symptoms of Crohn's disease, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, chronic severe plaque psoriasis and rheumatoid arthritis; Topamax (topiramate), an anti-epileptic and migraine prevention treatment; Levaquin (levofloxacin) and Floxin (ofloxacin), both in the anti-infective field; Duragesic/Fentanyl Transdermal (fentanyl transdermal system, sold outside the US as Durogesic ), a treatment for chronic pain; Ortho Evra (norelgestromin/ethinyl estradiol transdermal system), a contraceptive patch and Ortho Tri-Cyclen LO (norgestimate/ethinyl estradiol), an oral contraceptive; Concerta (methylphenidate HCl) for attention deficit hyperactivity disorder; and Natrecor (nesiritide), for acutely decompensated congestive heart failure.J&J's medical devices and diagnostics division includes products used principally in the professional fields of physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. Distribution to these markets is done both directly to health care professionals and indirectly through surgical supply dealers and other dealers. Product lines include surgical implants, instruments, needles and sutures; blood glucose monitoring systems; wound closure devices; endoscopic instruments; orthopedic products for joint repair and replacement and for correcting spinal deformities; contact lenses; clinical chemistry systems; medical devices, including cardiovascular monitoring and vascular access products; intravenous catheters and shunts; coronary and biliary stents.Key Metrics:Metric 2003200420052006 2007 Revenues 41,862.047,348.050,514.053,324.0 61,095.0 Net Income 7,197.08,180.010,060.011,053.0 10,576.0 Profit Margin 17.2%17.3%19.9%20.7% 17.3% Total Assets 48,263.053,317.058,864.070,556.0 80,954.0 Total Liabilities 21,394.021,504.020,154.031,238.0 37,635.0 Employees 110,600109,900115,600122,200 119,200 Figures are in US$ million except for employees and margin growthSource: Company Filings D A T A M O N I T O RDISTRIBUTIONCHAPTER 8 DISTRIBUTIONPharmacies and drugstores distribute 56.2% of the Chinese OTC pharmaceuticalsmarket's value.In comparison, specialist retailers distribute 12% of the market's value.ShareChannel % Pharmacies / drugstores 56.20%Specialist Retailers 12.00%Independent Retailers 11.20%Supermarkets / hypermarkets 4.00%Other 16.60%Total 100.0%Source: DatamonitorD A T A M O N I T O RMARKET FORECASTSCHAPTER 9 MARKET FORECASTS9.1 Market Value ForecastIn 2013, the Chinese OTC pharmaceuticals market is forecast to have a value of$21.9 billion, an increase of 36.0% since 2008.The compound annual growth rate of the market in the period 2008-2013 is predictedto be 6.3%.yuanGrowth% Year $billion RMBbillion2008 16.1 122.9 7.10%2009 17.3 131.4 7.00%2010 18.4 140.3 6.80%2011 19.6 149.6 6.60%2012 20.8 158.3 5.80%2013 21.9 167.1 5.60%CAGR, 2008-2013: 6.3%Source: Datamonitor D A T A M O N I T O RCHAPTER 10 MACROECONOMIC INDICATORSYear Population(million)%Growth2004 1298.82005 1306.30.60%2006 1314.00.60%2007 1321.90.60%2008(e) 1330.00.60%Source: Datamonitor D A T A M O N I T O RYearConstant 2000Prices, $ billion% Growth2004 1713.72005 1889.610.30% 2006 2094.210.80% 2007 2333.011.40% 2008(e) 2561.69.80% Source: Datamonitor D A T A M O N I T O RYear Inflation Rate (%)% Growth 2004 3.92005 1.8-54.00% 2006 1.5-16.70% 2007 4.8220.00% 2008(e) 5.514.80% Source: Datamonitor D A T A M O N I T O RYear Exchange Rate ($/RMB yuan)2004 0.120672005 0.12192006 0.125282007 0.131282008(e) 0.14365Source: Datamonitor D A T A M O N I T O RCHAPTER 11 APPENDIX11.1 MethodologyDatamonitor Industry Profiles draw on extensive primary and secondary research, allaggregated, analyzed, cross-checked and presented in a consistent and accessible style.Review of in-house databases – Created using 250,000+ industry interviews and consumer surveys and supported by analysis from industry experts using highly complex modeling & forecasting tools, Datamonitor’s in-house databases provide thefoundation for all related industry profiles.Preparatory research – We also maintain extensive in-house databases of news, analyst commentary, company profiles and macroeconomic & demographic information, which enable our researchers to build an accurate market overview.Definitions – Market definitions are standardized to allow comparison from country tocountry. The parameters of each definition are carefully reviewed at the start of the research process to ensure they match the requirements of both the market and our clients.Extensive secondary research activities ensure we are always fully up-to-date withthe latest industry events and trends.Datamonitor aggregates and analyzes a number of secondary information sources, including:• National/Governmental statistics•International data (official international sources)•National and International trade associations•Broker and analyst reports•Company Annual Reports•Business information libraries and databasesModeling & forecasting tools – Datamonitor has developed powerful tools that allow quantitative and qualitative data to be combined with related macroeconomic and demographic drivers to create market models and forecasts, which can then be refined according to specific competitive, regulatory and demand-related factors.Continuous quality control ensures that our processes and profiles remain focused,accurate and up-to-date.。